Pharming Group (PHAR) Earnings Analysis

Pharming Group (PHAR) next reports earnings on 2026-07-30, consensus EPS 0.063 USD. Last quarter (2026-05-07) it missed with EPS -0.07 USD vs 0.05 USD est (-240%). It has beaten estimates in 3/8 recent quarters (38%). Trailing P/E 65.66.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does PHAR next report earnings?

Next earnings date2026-07-30
Consensus EPS estimate0.063 USD
Revenue estimate0.10B

PHAR earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-0.07 USD0.05 USD-240%Miss
2026-03-120.07 USD0.15 USD-53.3%Miss
2025-11-060.1 USD0.05 USD+100%Beat
2025-07-310.06 USD-0.1 USD+160%Beat
2025-05-08-0.22 USD-0.025 USD-780%Miss
2025-03-130.05 USD0.019 USD+163.2%Beat
2024-10-24-0.02 USD0.01 USD-300%Miss
2024-08-01-0.01 USD-0.002 USD-400%Miss

Beat rate: 3/8 (38%) over reported quarters with consensus data.

PHAR valuation and analyst view

Trailing P/E65.66
Trailing EPS0.17 USD
Price / book3.54
Dividend yield0.00%
Market cap0.94B
Analyst consensusBuy (2 buy / 0 hold / 0 sell)
Avg price target40 USD

Related research pages

Frequently asked questions

When is Pharming Group (PHAR)'s next earnings date?

Pharming Group is next scheduled to report on 2026-07-30, with a consensus EPS estimate of 0.063 USD and revenue estimate of 0.10B.

Did PHAR beat earnings last quarter?

In its 2026-05-07 report, PHAR posted EPS of -0.07 USD versus a 0.05 USD estimate — a miss of 240%.

What is PHAR's earnings track record?

Over the last 8 reported quarters with consensus data, PHAR beat estimates 3 times (38%).

What is PHAR's current P/E ratio and EPS?

PHAR trades at a trailing P/E of 65.66 on trailing EPS of 0.17 USD.

What do analysts rate PHAR?

Analyst consensus is "Buy" across 2 ratings (0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 40 USD.